Medical network - March 13 "expensive" has always been the focus of media attention, is also common people complain about pain points. Since the reform, the provincial family planning are medical cost control as a priority to grasp, reduce the medical cost by reversed transmission hospital, and then solve the problem of difficulty and high cost of treatment, strengthen the citizen health reform get feeling. This measure is to made a profound impact on bidding for examination and approval of drugs.
Compared with imported drug prices are higher, quality of domestic generics in the tender competition advantage in the increasingly obvious.
Antibiotic drugs, for example, 2015-2016 in domestic antibiotic drug centralized purchasing, with high quality level (the first/second quality level) in guangdong, guangxi, tianjin and other places have won the bid, such as domestic antibiotic imine culture south). This year, a new round of antibiotic drug approval the bidding process is coming, huge demand from the healthcare industry is expected to further good domestic antibiotic generics.
▍ phenomenon and trend of domestic antibiotics generic word of mouth and demand
In recent years, domestic antibiotic generics are more and more from doctors, patients and the society of trust and praise.
First of all, the domestic high-quality generic antibiotics as foreign branded drug efficacy, and safety, and have price advantage, increasingly win the domestic consumer word of mouth. Along with the regular treatment knowledge popularization and continuously validated clinical therapeutic effect and safety, more and more patients to correct the wrong cognition of the generic drugs, "generics = counterfeit" the erroneous zone. Many consumers are changing concept of misunderstanding before, generic independent requirements of doctors' prescriptions.
Second, compared with the normal, the doctor groups are increasingly for generic drug prescription domestic antibiotics, patients with the reason: one is the digital age, consumers get information on drug quality channels increasingly diversified, the idea of a scientific and rational use of drugs to form, no longer susceptible to import expensive medicine; 2 it is domestic high-quality generic antibiotics its obvious advantage, good curative effect, and reduce the patients' family economic burden. In patients with good reputation and won the doctor professional reputation; 3 it is to the promotion of the national macro policy to control the medical cost, further influence the doctor to the patient's clinical drug use.
Overall, generics in quick meet medical demand, lower prices, reduce the medical cost has important role. In recent years, under the macro policy guidance, the provincial drug called sunshine standard policy further from the original drug leaning to generics. In the next few years, the domestic macro policy and antibiotic medicine development situation, generics companies will continue to be good quality domestic antibiotics, domestic antibiotic for further growth.
▍ prospect and countermeasures: three parties together, booster antibiotic generics rising powers
Throughout antibiotic market in China, the pattern is very clear. Antibiotic market in China is in the critical period of transformation. On the one hand, in order to cope with fierce competition from generic drugs, Merck and Pfizer branded drug companies have been trying to through research and development of new varieties and other means to consolidate its position in the field of antibiotics. "Consistency evaluation", on the other hand, accelerate the domestic antibiotic market reshuffle, brand advantage and innovation ability of excellent enterprise and product occupies, prop up national brand industry. As a leading company of antibiotics in China sea are Pfizer to "international quality, the national price" as the product positioning, in order to "green synthesis" technology as the forerunner, won the domestic ICU, blood, breath, and the surgeon a wide range of trust, and through cost-effective to severe infection in the empirical treatment of choice.
Facing new market pattern, the health department, national regulators should be combined with the enterprise, leading from antibiotics generic power to power in our country.
Health departments should further strengthen public education, through a variety of formal channels to the popularity of "generic antibiotics" scientific knowledge, further guide the patients to set up correct and reasonable medication concept, dispel medicine ", and the price is high efficacy "myth.
First of all, let the public know that generics are not what most people think of "Chinese characteristics".
Generic drugs is a huge social and public wealth, compared with the original drug price is low, improve the medical service level, reduce the medical expenses, maintain public health and good economic benefit and social benefit, both the European and American pharmaceutical developed countries and some emerging countries, generic drugs are the mainstream of drug consumption. Encourage the use of cheaper generic drugs is the trend of The Times, such as Germany, the generic drugs throughout its ratio of drug retail market has more than 40%.
In addition, the health departments should actively construct platform for international exchanges, promote domestic enterprises to absorb international experience, establish and improve quality of generic drugs and curative effect evaluation of consistency of international cooperation coordination mechanism, to build China with other countries drug information service platform and application for registration of supply and demand, strengthen the research of the major issues of international cooperation of generic drugs, learn from each other, complement each other, improve drug efficacy, safety, and quality control level. At the same time, to speed up the support excellent innovative enterprises, support r&d, put an end to the low level of generic and low profit of the malignant competition on price.
Drug regulatory departments should further guide regional drug bid evaluation standards, and reduce the medical cost as important factors are the key consideration; Enterprise itself will be expected to seize the opportunities for development, maintain and continue to innovate and improve product quality, facing the competition of foreign branded medicines, create cost-effective quality products, stable its own competitive advantage.
Family planning department of public health continue to standardize management of the clinical application of antibacterial drugs, will adopt the popular now? Negative list? Mode:
First, further clear the different level of the use of antimicrobial agents, for some medical staff some antimicrobial agents can not use;
Second, in certain disease states or diseases do not allow the use of antimicrobial agents, will organize experts clear diseases;
Third, explicitly limit use of antimicrobial agents should be medical institutions examination ability.
At present, the bacterial drug resistance has become a major global public health challenges, and governments and the social widespread attention worldwide problems.
Hangzhou's G20 summit in 2016, bacterial drug resistance was placed on the main issues, and writing of the final communique; On the 71th United Nations general assembly, the countries all over the world to the problem of bacterial resistance are discussed, the fourth health issue in the United Nations general assembly to discuss history. Bacterial resistance has expanded from health to political and economic fields.
In March 2017, the general office of the national health and family planning commission on further strengthen the management of clinical application of antibacterial drugs contain bacteria resistant notice issued, the requirement of various medical institutions at all levels should be institutions are formulated in accordance with the requirements of antibacterial drug supply catalog, physicians use antimicrobial prescription authority at all levels, including carbon penicillium alkene antimicrobial drug injection dosage form strict control in the three rules.
Under this big background, antibiotics related industry will face more and more serious challenge, many enterprises in the industry will also begin to experience a brutal shuffling, and quality varieties or will be there to share more market, seize the opportunity of integration. |
